The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | AEs associated with CAR-T in patients with triple-class exposed R/R MM: analysis from KarMMa-3
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, comments on safety outcomes in the KarMMa-3 trial (NCT03651128) comparing CAR T-cell (CAR-T) therapy to standard triplet combinations for triple-class-exposed relapsed/refractory (R/R) multiple myeloma (MM). While initial severity of cytopenias and rates of infections are elevated with CAR-T therapy, this recovers after ~3 months, eliminating overall safety concerns associated with this type of therapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
